Mar 17, 2008 by Brian Orelli, PhDDrugmakers That Make Rivals Green With EnvyA look at some drugmakers with cash to spend.
Mar 14, 2008 by Brian Orelli, PhDNo Slowdown for China's WuXiWuXi signs more drug development deals and buys a U.S. manufacturing services company.
Mar 14, 2008 by Brian Orelli, PhDWeighing In on Obesity DrugsCould investing in these drugmakers fatten your wallet?
Mar 14, 2008 by Brian Orelli, PhDALS: The Disease That Kills DrugsTeva's Copaxone doesn't help patients with Lou Gehrig's disease.
Mar 13, 2008 by Brian Orelli, PhDProgenics Down but Not OutIts drug to help patients after abdominal surgery fails in its phase 3 trial.
Mar 13, 2008 by Brian Orelli, PhDHumana's HurtingThe health insurer's miscalculation causes it to drop guidance.
Mar 12, 2008 by Brian Orelli, PhDWill This Drug Help Schering-Plough Recover?FDA approval of Bridion looks certain, but will doctors see a need for it?
Mar 11, 2008 by Brian Orelli, PhDWellPoint Is Not WellCosts up. Membership down. Not what the doctor ordered.
Mar 10, 2008 by Brian Orelli, PhDBreakup Weighs Down APPIt's going to take awhile for the pharmaceutical company to reward investors.
Mar 7, 2008 by Brian Orelli, PhDA Heavy Price for Wyeth and PfizerThey're ordered to pay millions because their hormone therapies may carry a higher risk of breast cancer.
Mar 7, 2008 by Brian Orelli, PhDInsurers' Tarnished Reputations ShineFind out which ones rank lowest -- and why it doesn't matter.
Mar 7, 2008 by Brian Orelli, PhDOpaque Omrix DisappointsNo guidance on the bottom line makes investors frown.
Mar 6, 2008 by Brian Orelli, PhDThe Biochip BattleBiochip makers Affymetrix and Illumina are duking it out.
Mar 5, 2008 by Brian Orelli, PhDTeva Wants the FDA to Do What?Teva wants the FDA to reinstate another drugmaker's patent.
Mar 5, 2008 by Brian Orelli, PhDFDA (Indirectly) Thwacks AmylinThe FDA's draft guidance puts a cloud of uncertainty over the makers of diabetes drugs.
Mar 5, 2008 by Brian Orelli, PhDYasmin Raises the Revenue BarrBarr gets a patent on Bayer's Yasmin overturned.
Mar 4, 2008 by Brian Orelli, PhDStaying at Par?Par Pharmaceutical had a good 2007, but can it sustain the momentum?
Feb 29, 2008 by Brian Orelli, PhDBigger Recall, No Big DealBaxter increases its recall of heparin, but investors shouldn't be that worried.
